Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
LMWHs are widely used in diverse patient groups (renal impairment, pregnancy, obesity), but the value of anti-Xa monitoring remains unclear.
This systematic review of 48 studies (RCTs and observational) found:
- Comparable bleeding and VTE rates in monitored vs. unmonitored patients.
- Frequent dose adjustments in monitored cohorts.
- Weak or absent correlation between anti-Xa levels and clinical outcomes.
Current evidence does not support routine anti-Xa monitoring for LMWH dose adjustment.”
Read the full paper in JTH.
Article: A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
Authors: Tessa C. C. Jaspers, P. Christian Remmelzwaal, Eefje P.S. Weersink, Karina Meijer, Nakisa Khorsand
Stay updated on all science in the field of anticoagulation with Hemostasis Today.
-
Jul 23, 2026, 15:58Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
-
Jul 23, 2026, 15:43Lorna Knight: The Next Frontier in Sickle Cell Disease Is Access
-
Jul 23, 2026, 15:29Ben Kleinstiver: Overcoming a Major Barrier to Scalable Gene Editing
-
Jul 23, 2026, 15:28Modernizing DIC Diagnosis in Cirrhosis: Building an International Registry for Precision Hemostasi
-
Jul 23, 2026, 14:32Saneha Anjum Shaikh: Why Antibody Screening Must Be Standard Practice in Modern Blood Banking
-
Jul 23, 2026, 14:00Ron Vezina: Canadian Blood Services Issues Urgent Donation Appeal
-
Jul 23, 2026, 13:46Sebastian Szmit: Understanding Troponins in Modern Cardio-Oncology
-
Jul 23, 2026, 13:41Colleen Grady: Why Normal Hemoglobin Does Not Exclude Iron Deficiency
-
Jul 23, 2026, 13:22Jacob Kelly: AHA Review Highlights Coffee’s Cardiovascular Benefits